SG11201900361RA - Methods of treating prostate cancer - Google Patents
Methods of treating prostate cancerInfo
- Publication number
- SG11201900361RA SG11201900361RA SG11201900361RA SG11201900361RA SG11201900361RA SG 11201900361R A SG11201900361R A SG 11201900361RA SG 11201900361R A SG11201900361R A SG 11201900361RA SG 11201900361R A SG11201900361R A SG 11201900361RA SG 11201900361R A SG11201900361R A SG 11201900361RA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- applicant
- johnson
- road
- pct
- Prior art date
Links
- 206010060862 Prostate cancer Diseases 0.000 title abstract 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- PCHKPVIQAHNQLW-CQSZACIVSA-N niraparib Chemical compound N1=C2C(C(=O)N)=CC=CC2=CN1C(C=C1)=CC=C1[C@@H]1CCCNC1 PCHKPVIQAHNQLW-CQSZACIVSA-N 0.000 abstract 3
- 229950011068 niraparib Drugs 0.000 abstract 3
- 238000000338 in vitro Methods 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 208000023958 prostate neoplasm Diseases 0.000 abstract 1
- 102220240796 rs553605556 Human genes 0.000 abstract 1
- 210000004881 tumor cell Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 1 Ill IOU 0 11101 010 11111 01 110 1 0 011101 0111 001 11111 010 1111 MEV OEM Organization International Bureau (10) International Publication Number (43) International Publication Date .....0\"\"\" WO 2018/023017 Al 01 February 2018 (01.02.2018) WIP0 I PCT (51) (21) (22) (25) Filing Language: (26) (30) (71) (72) (71) — (72) International Patent Classification: DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, A61K 31/454 (2006.01) A61P 35/00 (2006.01) HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, International Application Number: KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, PCT/US2017/044413 MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, International Filing Date: SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, 28 July 2017 (28.07.2017) TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. English (84) Designated States (unless otherwise indicated, for every Publication Language: English kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, Priority Data: UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, 62/368,466 29 July 2016 (29.07.2016) US TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, 62/369,239 01 August 2016 (01.08.2016) US EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, Applicant: JANSSEN PHARMACEUTICA NV TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, [BE/BE]; Turnhoutseweg 30, B-2340 Beerse (BE). KM, ML, MR, NE, SN, TD, TG). Inventor; and Applicant: GOTTARDIS, Marco [US/US]; 9 Harris Declarations under Rule 4.17: Road, Princeton, New Jersey 08540 (US). — as to applicant's entitlement to apply for and be granted a patent (Rule 4. 17(ii)) Inventors: HAWKINS, Rebecca; 1400 McKean Road, — as to the applicant's entitlement to claim the priority of the Spring House, 19477 (PA). SNYDER, Linda; 1400 McK- earlier application (Rule 4 . 17 (iii)) can Road, Spring House, Pennsylvania 19477 (US). YA- MADA, Douglas H.; 1400 McKean Road, Spring House, Published: Pennsylvania 19477 (US). — with international search report (Art. 21(3)) Agent: SHIRTZ, Joseph F. et al.; Johnson & Johnson, One Johnson & Johnson Plaza, New Brunswick, New Jer- sey 08933 (US). Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, — = (74) = (81) = = = Title: METHODS OF TREATING 100- 80- o c 60- ..m Tb 40- • - = c ._ 'e,.. ' 20 - 0 - 20 . 4 PROSTATE CANCER = (54) = = = = - • -A- C4-2B -A- LnCaP • = = • • • ...vir ...•- -yr- LnCaP AR.TB -e- VCaP -N- 22Rv 1 — = 1-1 IN 1-1 O M N 0 --.... 00 1-1 0 N (57) 0 Figure 1. : Disclosed are methods -2 . . . . . -1 0 1 2 3 log [niraparib], All Niraparib inhibits the growth of human prostate tumor cell lines in vitro. of treating prostate cancer by administering niraparib to a subject in need thereof.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662368466P | 2016-07-29 | 2016-07-29 | |
| US201662369239P | 2016-08-01 | 2016-08-01 | |
| PCT/US2017/044413 WO2018023017A1 (en) | 2016-07-29 | 2017-07-28 | Methods of treating prostate cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201900361RA true SG11201900361RA (en) | 2019-02-27 |
Family
ID=59649991
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201900361RA SG11201900361RA (en) | 2016-07-29 | 2017-07-28 | Methods of treating prostate cancer |
Country Status (20)
| Country | Link |
|---|---|
| US (8) | US20180028521A1 (en) |
| EP (1) | EP3490560A1 (en) |
| JP (3) | JP2019522032A (en) |
| KR (2) | KR20240115925A (en) |
| CN (1) | CN109640991A (en) |
| AU (2) | AU2017302660B2 (en) |
| BR (1) | BR112019001398A2 (en) |
| CA (1) | CA3031705A1 (en) |
| CO (1) | CO2019000753A2 (en) |
| DO (1) | DOP2019000019A (en) |
| IL (1) | IL264443A (en) |
| MA (1) | MA45780A (en) |
| MX (2) | MX2019001224A (en) |
| NI (1) | NI201900009A (en) |
| PE (1) | PE20190403A1 (en) |
| PH (1) | PH12019500135A1 (en) |
| SG (1) | SG11201900361RA (en) |
| SV (1) | SV2019005822A (en) |
| UA (1) | UA124972C2 (en) |
| WO (1) | WO2018023017A1 (en) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10865184B2 (en) | 2015-04-21 | 2020-12-15 | University Of Tennessee Research Foundation | Selective androgen receptor degrader (SARD) ligands and methods of use thereof |
| US10441570B2 (en) | 2015-04-21 | 2019-10-15 | University Of Tennessee Research Foundation | Selective androgen receptor degrader (SARD) Ligands and methods of use thereof |
| US10093613B2 (en) | 2015-04-21 | 2018-10-09 | Gtx, Inc. | Selective androgen receptor degrader (SARD) ligands and methods of use thereof |
| US10806720B2 (en) | 2015-04-21 | 2020-10-20 | University Of Tennessee Research Foundation | Selective androgen receptor degrader (SARD) ligands and methods of use thereof |
| PE20190403A1 (en) | 2016-07-29 | 2019-03-13 | Janssen Pharmaceutica Nv | METHODS TO TREAT PROSTATE CANCER |
| KR20200105862A (en) * | 2017-12-27 | 2020-09-09 | 테사로, 인코포레이티드 | How to treat cancer |
| US20210196678A1 (en) * | 2018-05-16 | 2021-07-01 | University Of Tennessee Research Foundation | Selective androgen receptor degrader (sard) ligands and methods of use thereof |
| WO2020051344A1 (en) * | 2018-09-05 | 2020-03-12 | University Of Tennessee Research Foundation | Selective androgen receptor degrader (sard) ligands and methods of use thereof |
| CA3223426A1 (en) * | 2021-07-19 | 2023-01-26 | Peter Francis | Treatment of metastatic castration-resistant prostate cancer with niraparib |
Family Cites Families (128)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5120722A (en) | 1984-02-08 | 1992-06-09 | Hoffmann-La Roche Inc. | Trihydroxy-cholecacliferol and trihydroxy-ergocalciferol for treating leukemia |
| US4857518A (en) | 1984-10-04 | 1989-08-15 | Wisconsin Alumni Research Foundation | Hydroxylated 24-homo-vitamin D derivatives and methods for preparing same |
| US4717721A (en) | 1985-05-30 | 1988-01-05 | Howard W. Bremer | Sidechain homo-vitamin D compounds with preferential anti-cancer activity |
| WO1987000834A1 (en) | 1985-08-02 | 1987-02-12 | Leo Pharmaceutical Products Ltd. A/S | Novel vitamin d analogues |
| US5145846A (en) | 1988-01-20 | 1992-09-08 | Hoffmann-La Roche Inc. | Vitamin D3 analogs |
| US4851401A (en) | 1988-07-14 | 1989-07-25 | Wisconsin Alumni Research Foundation | Novel cyclopentano-vitamin D analogs |
| CA1333616C (en) | 1989-03-09 | 1994-12-20 | Hector F. Deluca | 19-nor-vitamin d compounds |
| GB8915770D0 (en) | 1989-07-10 | 1989-08-31 | Leo Pharm Prod Ltd | Chemical compounds |
| US4966898A (en) | 1989-08-15 | 1990-10-30 | Merrell Dow Pharmaceuticals Inc. | 4-substituted 17β-(cyclopropylamino)androst-5-en-3β-ol and related compounds useful as C17-20 lyase inhibitors |
| DE4021433A1 (en) | 1990-07-04 | 1992-01-09 | Schering Ag | ANTIANDROGEN WITH STEROID (3,2-C) PYRAZOLE STRUCTURE |
| DE4101953A1 (en) | 1991-01-19 | 1992-07-23 | Schering Ag | 23-OXA DERIVATIVES IN THE VITAMIN-D SERIES, METHOD FOR THE PRODUCTION THEREOF THE PHARMACEUTICAL PREPARATIONS CONTAINING THESE DERIVATIVES AND THE USE THEREOF AS MEDICINAL PRODUCTS |
| DE4141746A1 (en) | 1991-12-13 | 1993-06-17 | Schering Ag | 20-METHYL-SUBSTITUTED VITAMIN D DERIVATIVES |
| AU668144B2 (en) | 1992-03-31 | 1996-04-26 | Btg International Limited | 17-substituted steroids useful in cancer treatment |
| US5604213A (en) | 1992-03-31 | 1997-02-18 | British Technology Group Limited | 17-substituted steroids useful in cancer treatment |
| US5547947A (en) | 1993-03-11 | 1996-08-20 | Hoffmann-La Roche Inc. | Methods of treatment |
| DK0721461T3 (en) | 1993-09-30 | 1999-09-20 | Btg Int Ltd | Synthesis of 17- (3-pyridyl) steroids |
| US5688977A (en) | 1996-02-29 | 1997-11-18 | Napro Biotherapeutics, Inc. | Method for docetaxel synthesis |
| US5919815A (en) | 1996-05-22 | 1999-07-06 | Neuromedica, Inc. | Taxane compounds and compositions |
| US5795909A (en) | 1996-05-22 | 1998-08-18 | Neuromedica, Inc. | DHA-pharmaceutical agent conjugates of taxanes |
| ES2151277T3 (en) | 1996-05-22 | 2000-12-16 | Protarga Inc | COMPOSITIONS INCLUDING CONJUGATES OF CIS-DOCOSAHEXAENOIC ACID AND TAXOTERE. |
| GB9622590D0 (en) | 1996-10-30 | 1997-01-08 | Leo Pharm Prod Ltd | Chemical compounds |
| US20020128240A1 (en) | 1996-12-30 | 2002-09-12 | Bone Care International, Inc. | Treatment of hyperproliferative diseases using active vitamin D analogues |
| US6872568B1 (en) | 1997-03-17 | 2005-03-29 | Human Genome Sciences, Inc. | Death domain containing receptor 5 antibodies |
| US20050233958A1 (en) | 1997-03-17 | 2005-10-20 | Human Genome Sciences, Inc. | Death domain containing receptor 5 |
| US6087350A (en) | 1997-08-29 | 2000-07-11 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Use of pretreatment chemicals to enhance efficacy of cytotoxic agents |
| AU762481C (en) | 1998-03-27 | 2004-08-19 | Oregon Health Sciences University | Vitamin D and its analogs in the treatment of tumors and other hyperproliferative disorders |
| US20030083231A1 (en) | 1998-11-24 | 2003-05-01 | Ahlem Clarence N. | Blood cell deficiency treatment method |
| IL143870A0 (en) | 1998-12-23 | 2002-04-21 | Searle & Co | Method of using a cyclooxygenase-2 inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia |
| EP1276482B1 (en) | 2000-03-02 | 2008-01-16 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Combination chemotherapy |
| EP1284272A4 (en) | 2000-04-24 | 2003-09-10 | Kyowa Hakko Kogyo Kk | Estra-1,3,5(10)-triene derivatives |
| EP1676577A1 (en) | 2000-05-15 | 2006-07-05 | Celgene Corporation | Compositions for the treatment of cancer comprising a topoisomerase inhibitor and thalidomide |
| EP1307197B1 (en) | 2000-05-15 | 2006-04-05 | Celgene Corporation | Compositions for the treatment of cancer comprising a topoisomerase inhibitor and thalidomide |
| CN1254234C (en) | 2000-06-09 | 2006-05-03 | 莱古伦公司 | Plasmid DNA (Lipogenes TM) and nucleas-containing location signal/fusogene conjogates drug encapsulating into targeted liposomes complex |
| WO2002003286A1 (en) | 2000-07-05 | 2002-01-10 | Bryan Muehlberger | Systems and methods of facilitating electronic payment transactions |
| US6656942B2 (en) | 2000-10-17 | 2003-12-02 | Merck & Co., Inc. | Orally active salts with tyrosine kinase activity |
| US6750213B2 (en) | 2000-10-19 | 2004-06-15 | Merck & Co., Inc. | Estrogen receptor modulators |
| DE10061137B4 (en) | 2000-12-07 | 2016-10-06 | Takeda Gmbh | New pharmaceutical preparation |
| US20040092583A1 (en) | 2001-01-02 | 2004-05-13 | Elizabeth Shanahan-Prendergast | Treatment for inhibiting neoplastic lesions |
| US6872733B2 (en) | 2001-04-18 | 2005-03-29 | Euro-Celtique S.A. | Benzimidazolone compounds |
| CA2443938C (en) | 2001-04-18 | 2010-06-22 | R. Richard Goehring | Spiroindene and spiroindane compounds as opioid ligands useful for treating pain |
| EP2050450A1 (en) | 2001-04-18 | 2009-04-22 | Euro-Celtique S.A. | 1-Piperidine-2-cyanoimino-1,3-dihydro-2H-benzimidazole derivatives as nociceptin analogs with ORL1 modulating activity for the treatment of pain |
| WO2002085355A1 (en) | 2001-04-18 | 2002-10-31 | Euro-Celtique, S.A. | Spiropyrazole compounds |
| EP1387821A2 (en) | 2001-05-10 | 2004-02-11 | Merck & Co., Inc. | Estrogen receptor modulators |
| WO2002102783A1 (en) | 2001-06-19 | 2002-12-27 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| US6740641B2 (en) | 2001-07-27 | 2004-05-25 | Euro-Celtique, S.A. | Sugar derivatives of hydromorphone, dihydromorphine and dihydromorphine, compositions thereof and uses for treating or preventing pain |
| AU2002323406A1 (en) | 2001-08-30 | 2003-03-18 | Merck And Co., Inc. | Tyrosine kinase inhibitors |
| AR036492A1 (en) | 2001-09-06 | 2004-09-15 | Schering Corp | INHIBITORS OF THE 17BETA-HYDROXIESTEROID DEHYDROGENASE TYPE 3, PHARMACEUTICAL COMPOSITIONS AND THE USE OF SUCH INHIBITORS FOR THE PREPARATION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF DEPENDING ANDROGEN DISEASES |
| US7169788B2 (en) | 2001-10-30 | 2007-01-30 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| CA2465491A1 (en) | 2001-11-07 | 2003-05-15 | Merck & Co., Inc. | Mitotic kinesin inhibitors |
| CA2467722A1 (en) | 2001-12-06 | 2003-06-19 | Merck & Co., Inc. | Thienopyrimidinone derivatives as mitotic kinesin inhibitors |
| WO2005016236A2 (en) | 2003-05-06 | 2005-02-24 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to trail receptors |
| JP4583760B2 (en) | 2002-02-01 | 2010-11-17 | ユーロ−セルティーク エス．エイ． | Useful treatment for pain |
| EP1336602A1 (en) | 2002-02-13 | 2003-08-20 | Giovanni Scaramuzzino | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases |
| US6974818B2 (en) | 2002-03-01 | 2005-12-13 | Euro-Celtique S.A. | 1,2,5-thiadiazol-3-YL-piperazine therapeutic agents useful for treating pain |
| WO2003075958A1 (en) | 2002-03-11 | 2003-09-18 | Takeda Chemical Industries, Ltd. | Remedies for sex hormone-dependent disease |
| WO2003086404A1 (en) | 2002-04-08 | 2003-10-23 | Merck & Co., Inc. | Fused quinoxaline derivatives as inhibitors of akt activity |
| EP1927858B1 (en) | 2002-04-29 | 2013-01-09 | Euro-Celtique S.A. | Conformationally constrained peptides that bind the ORL-1 receptor |
| JP2005530745A (en) | 2002-05-02 | 2005-10-13 | メルク エンド カムパニー インコーポレーテッド | Tyrosine kinase inhibitor |
| CA2486215A1 (en) | 2002-06-14 | 2003-12-24 | Merck & Co., Inc. | Mitotic kinesin inhibitors |
| EP1556354B1 (en) | 2002-06-28 | 2008-01-23 | Euro-Celtique S.A. | Therapeutic piperazine derivates useful for treating pain |
| US7985422B2 (en) | 2002-08-05 | 2011-07-26 | Torrent Pharmaceuticals Limited | Dosage form |
| US8268352B2 (en) | 2002-08-05 | 2012-09-18 | Torrent Pharmaceuticals Limited | Modified release composition for highly soluble drugs |
| US8216609B2 (en) | 2002-08-05 | 2012-07-10 | Torrent Pharmaceuticals Limited | Modified release composition of highly soluble drugs |
| AU2003259835A1 (en) | 2002-08-15 | 2004-03-03 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to trail receptors |
| EP1539183A4 (en) | 2002-08-28 | 2007-04-25 | Hollis Eden Pharmaceuticals | Therapeutic treatment methods |
| US20050101581A1 (en) | 2002-08-28 | 2005-05-12 | Reading Christopher L. | Therapeutic treatment methods 2 |
| US7157462B2 (en) | 2002-09-24 | 2007-01-02 | Euro-Celtique S.A. | Therapeutic agents useful for treating pain |
| DE60318092T2 (en) | 2002-10-23 | 2008-11-27 | Pantarhei Bioscience B.V. | PHARMACEUTICAL COMPOSITION CONTAINING ESTETROL DERIVATIVES AND APPLICATION IN CANCER TREATMENT |
| JP2006507302A (en) | 2002-10-30 | 2006-03-02 | メルク エンド カムパニー インコーポレーテッド | Kinase inhibitor |
| US7202259B2 (en) | 2002-11-18 | 2007-04-10 | Euro-Celtique S.A. | Therapeutic agents useful for treating pain |
| CN1744930A (en) | 2002-12-17 | 2006-03-08 | 先灵公司 | 17 beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases |
| US7582635B2 (en) | 2002-12-24 | 2009-09-01 | Purdue Pharma, L.P. | Therapeutic agents useful for treating pain |
| US20050054620A1 (en) | 2003-01-13 | 2005-03-10 | Koeffler H. Phillip | Paricalcitol as a chemotherapeutic agent |
| TWI330079B (en) | 2003-01-15 | 2010-09-11 | Synta Pharmaceuticals Corp | Treatment for cancers |
| US20050020546A1 (en) | 2003-06-11 | 2005-01-27 | Novacea, Inc. | Pharmaceutical compositions comprising active vitamin D compounds |
| AR044688A1 (en) | 2003-06-12 | 2005-09-21 | Euro Celtique Sa | USEFUL THERAPEUTIC AGENTS FOR THE TREATMENT OF PAIN |
| ES2327684T3 (en) | 2003-07-24 | 2009-11-02 | Euro-Celtique S.A. | HETEROARIL-TETRAHIDROPIRIDILO COMPOUNDS USEFUL FOR THE TREATMENT OR PREVENTION OF PAIN. |
| PL1867644T3 (en) | 2003-07-24 | 2009-10-30 | Euro Celtique Sa | Heteroaryl-tetrahydropiperidyl compounds useful for treating or preventing pain |
| US7071333B2 (en) | 2003-07-30 | 2006-07-04 | Bristol-Myers Squibb Company | Triazolopurine-based tricyclic compounds and pharmaceutical compositions comprising same |
| SI1942106T1 (en) | 2003-08-01 | 2012-01-31 | Euro Celtique Sa | Therapeutic agents useful for treating pain |
| AU2004268707A1 (en) | 2003-08-27 | 2005-03-10 | Merck Frosst Canada Ltd | Cathepsin inhibitors |
| ES2317052T3 (en) | 2003-09-22 | 2009-04-16 | Euro-Celtique S.A. | USEFUL THERAPEUTIC AGENTS FOR THE TREATMENT OF PAIN. |
| DK2017276T3 (en) | 2003-09-22 | 2011-04-18 | Euro Celtique Sa | Phenylcarboxamide compounds for the treatment of pain |
| ATE369862T1 (en) | 2003-10-17 | 2007-09-15 | 4 Aza Ip Nv | HETEROCYCLUS-SUBSTITUTED PTERIDINE DERIVATIVES AND THEIR USE IN THERAPY |
| WO2005107801A2 (en) | 2004-04-29 | 2005-11-17 | The Regents Of The University Of Colorado | Systems and methods for treating human inflammatory and proliferative diseases, with a combination of fatty acid metabolism inhibitors and glycolytic inhibitors and/or ucp and/or fas antibodies |
| US7094775B2 (en) | 2004-06-30 | 2006-08-22 | Bone Care International, Llc | Method of treating breast cancer using a combination of vitamin D analogues and other agents |
| US20060003950A1 (en) | 2004-06-30 | 2006-01-05 | Bone Care International, Inc. | Method of treating prostatic diseases using a combination of vitamin D analogues and other agents |
| US20060030608A1 (en) | 2004-08-04 | 2006-02-09 | Boehringer Ingelheim Pharmaceuticals, Inc. | Anti aromatase compounds pharmaceutical compositions and uses thereof |
| GB0418900D0 (en) | 2004-08-24 | 2004-09-29 | Btg Int Ltd | Novel salt forms |
| WO2006027266A1 (en) | 2004-09-10 | 2006-03-16 | Nitec Pharma Ag | Tablets with site time-controlled gastrointestinal release of active ingredient |
| AR051597A1 (en) | 2004-11-01 | 2007-01-24 | Merck & Co Inc | MODULATORS OF STROGEN RECEIVERS |
| EP1674479A1 (en) | 2004-12-22 | 2006-06-28 | Memorial Sloan-Kettering Cancer Center | Modulation of Fc Gamma receptors for optimizing immunotherapy |
| WO2006081152A2 (en) | 2005-01-24 | 2006-08-03 | Merck & Co., Inc. | Estrogen receptor modulators |
| US20100087474A1 (en) | 2005-04-27 | 2010-04-08 | University Of Florida | Materials and methods for enhanced degradation of mutant proteins associated with human disease |
| WO2006116217A2 (en) | 2005-04-28 | 2006-11-02 | The Regents Of The University Of Colorado | Therapeutic bifunctional compounds |
| US7709517B2 (en) | 2005-05-13 | 2010-05-04 | The Regents Of The University Of California | Diarylhydantoin compounds |
| KR20080033463A (en) | 2005-07-27 | 2008-04-16 | 유니버시티 오브 플로리다 리서치 파운데이션, 아이엔씨. | Small compounds that correct protein misfolding and uses thereof |
| CA2647545C (en) | 2006-04-03 | 2016-02-23 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Amide substituted indazole and benzotriazole derivatives as poly(adp-ribose)polymerase (parp) inhibitors |
| CA2654174A1 (en) | 2006-06-02 | 2008-04-03 | Government Of The United States Of America, As Represented By The Secret Ary, Department Of Health And Human Services | Rna nanoparticles and nanotubes |
| WO2008005268A1 (en) | 2006-06-30 | 2008-01-10 | Schering Corporation | Substituted piperidines that increase p53 activity and the uses thereof |
| CN101511361A (en) | 2006-06-30 | 2009-08-19 | 先灵公司 | Method of using substituted piperidines that increase p53 activity |
| EP2478907B1 (en) | 2006-08-25 | 2021-04-14 | Janssen Oncology, Inc. | Compositions for treating cancer |
| US20080051375A1 (en) | 2006-08-25 | 2008-02-28 | Auerbach Alan H | Methods for treating cancer comprising the administration of a vitamin d compound and an additional therapeutic agent, and compositions containing the same |
| US20080051380A1 (en) | 2006-08-25 | 2008-02-28 | Auerbach Alan H | Methods and compositions for treating cancer |
| WO2008127290A2 (en) | 2006-10-12 | 2008-10-23 | The Johns Hopkins University | Alginate and alginate lyase compositions and methods of use |
| CA2679955A1 (en) | 2006-10-13 | 2008-05-29 | Reliance Life Sciences Pvt. Ltd. | Novel chemotherapeutic agents against inflammation and cancer |
| CA2674436C (en) | 2007-01-10 | 2012-07-17 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors |
| RU2009134223A (en) | 2007-02-15 | 2011-03-20 | Новартис АГ (CH) | COMBINATION OF LBH589 WITH OTHER THERAPEUTIC MEDICINES FOR THE TREATMENT OF CANCER |
| EP2139522A2 (en) | 2007-03-06 | 2010-01-06 | Colby Pharmaceutical Company | Mitochondria targeted cationic anti-oxidant compounds for prevention, therapy or treatment of hyper-proliferative disease, neoplasias and cancers |
| WO2009009132A1 (en) | 2007-07-12 | 2009-01-15 | Cougar Biotechnology, Inc. | Use of 17alpha-hydroxylase/c17, 20-lyase inhibitors for the treatment of cancer |
| BRPI0906020A2 (en) | 2008-01-08 | 2015-06-30 | Merck Sharp & Dohme | Pharmaceutically acceptable salts of 2- {4 - [(3s) -piperidin-3-yl] phenyl} -2h-indazol-7-carboxamide, use and method of treatment |
| MX2010010659A (en) | 2008-03-31 | 2010-10-26 | Genentech Inc | Benzopyran and benzoxepin pi3k inhibitor compounds and methods of use. |
| MX2010011924A (en) | 2008-05-07 | 2010-11-30 | Cardioxyl Pharmaceuticals Inc | Novel nitroso compounds as nitroxyl donors and methods of use thereof. |
| WO2012009475A1 (en) | 2010-07-14 | 2012-01-19 | Oregon Health & Science University | Methods of treating cancer with inhibition of lysine-specific demethylase 1 |
| US9314473B2 (en) | 2011-02-03 | 2016-04-19 | Pop Test Oncology Limited Liability Company | System and method for diagnosis and treatment |
| JP5804395B2 (en) | 2011-02-03 | 2015-11-04 | ポップ テスト オンコロジー エルエルシー | Systems and methods for diagnosis and treatment |
| WO2014089324A1 (en) | 2012-12-07 | 2014-06-12 | Calitor Sciences, Llc | Substituted cyclic compounds and methods of use |
| WO2014150000A1 (en) | 2013-03-21 | 2014-09-25 | Isp Investments Inc. | Diacetylene film sensitized with photoinitiator and applications of the film |
| US9192609B2 (en) | 2013-04-17 | 2015-11-24 | Hedgepath Pharmaceuticals, Inc. | Treatment and prognostic monitoring of proliferation disorders using hedgehog pathway inhibitors |
| WO2015164586A1 (en) | 2014-04-23 | 2015-10-29 | The Brigham And Women's Hospital, Inc. | Targeting parp1 for treatment of tsc and cancers |
| US20150344968A1 (en) | 2014-05-30 | 2015-12-03 | Institute For Cancer Research D/B/A The Research Institute Of Fox Chase Cancer Center | Methods for determining parp inhibitor and platinum resistance in cancer therapy |
| US20160160294A1 (en) | 2014-12-08 | 2016-06-09 | Tesaro | Methods and materials for predicting response to niraparib |
| WO2017023694A1 (en) | 2015-08-03 | 2017-02-09 | Pop Test Oncology Llc | Pharmaceutical compositions and methods |
| PE20190403A1 (en) * | 2016-07-29 | 2019-03-13 | Janssen Pharmaceutica Nv | METHODS TO TREAT PROSTATE CANCER |
| US11702443B2 (en) | 2016-10-04 | 2023-07-18 | Pop Test Oncology Llc | Therapeutic agents and methods |
| WO2018067520A2 (en) | 2016-10-04 | 2018-04-12 | Pop Test Oncology Llc | Therapeutic agents and methods: |
| JOP20190244A1 (en) | 2017-04-13 | 2019-10-13 | Janssen Pharmaceutica Nv | Combination therapy for prostate cancer |
| CA3077678A1 (en) | 2017-10-11 | 2019-04-18 | Janssen Oncology, Inc. | Methods of treating prostate cancer by administering abiraterone acetate plus prednisone with androgen deprivation therapy |
-
2017
- 2017-07-28 PE PE2019000269A patent/PE20190403A1/en unknown
- 2017-07-28 JP JP2019504790A patent/JP2019522032A/en not_active Withdrawn
- 2017-07-28 MX MX2019001224A patent/MX2019001224A/en unknown
- 2017-07-28 WO PCT/US2017/044413 patent/WO2018023017A1/en active Application Filing
- 2017-07-28 UA UAA201901979A patent/UA124972C2/en unknown
- 2017-07-28 SG SG11201900361RA patent/SG11201900361RA/en unknown
- 2017-07-28 BR BR112019001398-9A patent/BR112019001398A2/en not_active Application Discontinuation
- 2017-07-28 CA CA3031705A patent/CA3031705A1/en active Pending
- 2017-07-28 US US15/663,082 patent/US20180028521A1/en not_active Abandoned
- 2017-07-28 MA MA045780A patent/MA45780A/en unknown
- 2017-07-28 EP EP17754226.3A patent/EP3490560A1/en active Pending
- 2017-07-28 KR KR1020247023937A patent/KR20240115925A/en not_active Application Discontinuation
- 2017-07-28 KR KR1020197005783A patent/KR20190033599A/en not_active IP Right Cessation
- 2017-07-28 AU AU2017302660A patent/AU2017302660B2/en active Active
- 2017-07-28 CN CN201780046876.1A patent/CN109640991A/en active Pending
-
2018
- 2018-09-14 US US16/131,772 patent/US11207311B2/en active Active
-
2019
- 2019-01-18 PH PH12019500135A patent/PH12019500135A1/en unknown
- 2019-01-24 IL IL264443A patent/IL264443A/en unknown
- 2019-01-25 NI NI201900009A patent/NI201900009A/en unknown
- 2019-01-28 CO CONC2019/0000753A patent/CO2019000753A2/en unknown
- 2019-01-28 MX MX2023011187A patent/MX2023011187A/en unknown
- 2019-01-28 DO DO2019000019A patent/DOP2019000019A/en unknown
- 2019-01-28 SV SV2019005822A patent/SV2019005822A/en unknown
-
2021
- 2021-11-16 US US17/528,050 patent/US20220071980A1/en active Pending
- 2021-11-16 US US17/528,017 patent/US20220071979A1/en active Pending
-
2022
- 2022-05-25 JP JP2022084991A patent/JP7569353B2/en active Active
- 2022-11-17 US US17/989,420 patent/US11986468B2/en active Active
- 2022-11-17 US US17/989,462 patent/US11986469B2/en active Active
- 2022-11-17 US US17/989,329 patent/US11992486B2/en active Active
-
2023
- 2023-05-05 AU AU2023202813A patent/AU2023202813A1/en active Pending
- 2023-09-13 US US18/466,547 patent/US11986470B2/en active Active
-
2024
- 2024-07-23 JP JP2024117499A patent/JP2024150638A/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201900361RA (en) | Methods of treating prostate cancer | |
| SG11201903857UA (en) | Antibodies to pd-1 and uses thereof | |
| SG11201907846VA (en) | Therapeutic rna | |
| SG11201906386XA (en) | Combination therapy involving diaryl macrocyclic compounds | |
| SG11201808125RA (en) | Methods for solid tumor treatment | |
| SG11201901307VA (en) | Heterodimeric immunoglobulin constructs and preparation methods thereof | |
| SG11201806322QA (en) | Maytansinoid derivatives, conjugates thereof, and methods of use | |
| SG11201909155VA (en) | Ask1 inhibitor compounds and uses thereof | |
| SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
| SG11201908325PA (en) | Process for the preparation of glucuronide drug-linkers and intermediates thereof | |
| SG11201901986SA (en) | Process for the manufacture of a solid pharmaceutical adminstration form | |
| SG11201903032SA (en) | Methods and compositions related to nk cell and anti-pdl1 cancer therapies | |
| SG11201903771XA (en) | Binding molecules specific for asct2 and uses thereof | |
| SG11201909680UA (en) | Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds | |
| SG11201810965YA (en) | 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors | |
| SG11201805001UA (en) | Method of treating influenza a | |
| SG11201805311XA (en) | Method of treating a mammal, including human, against cancer using methionine and asparagine depletion | |
| SG11201805170XA (en) | Cellular glycosaminoglycan compositions and methods of making and using | |
| SG11201809630RA (en) | Nicotine particles | |
| SG11201909041SA (en) | Anti-pd-l1 antibody and use thereof | |
| SG11201807062RA (en) | Anti-tnfalpha-antibodies and functional fragments thereof | |
| SG11201903076QA (en) | Carbamoyl phenylalaninol compounds and uses therof | |
| SG11201803816RA (en) | Targeting of the formyl-peptide receptor 2/lipoxin a4 receptor (fpr2/alx) for treatment of heart disease | |
| SG11201906778RA (en) | Improved methods for assessing risk of developing breast cancer | |
| SG11201901048VA (en) | Pharmaceutical compositions and uses directed to lysosomal storage disorders |